Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on January 8, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in Cincinnati, Ohio. The filing serves as a Regulation FD disclosure to furnish a corporate presentation to investors.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary event is the release of a corporate presentation intended for use in investor meetings.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the attached corporate presentation (Exhibit 99.1) in meetings with investors and others beginning January 8, 2018. The presentation is also available on the Company's investor relations website.
Legal Disclaimer: The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the corporate presentation attached as Exhibit 99.1 for specific business updates.
- Confirm the availability of the presentation on the Company's website at http://aerpio.com.
- Note that the filing explicitly states the presentation is not "filed" for liability purposes under Section 18 of the Exchange Act.
- Review subsequent filings for actual financial data, as this 8-K contains no numerical financial metrics.